Suppression of Osteoclastogenesis in Rheumatoid Arthritis by Induction of Apoptosis in Activated CD4+ T Cells

Arthritis and Rheumatism

Volumn 48, Issue 12, 2003, Pages 3350-3358

  Ogawa, Yukie ^a,b   Ohtsuki, Masahiko ^a   Uzuki, Miwa ^c   Sawai, Takashi ^c   Onozawa, Yoshiko ^a   Nakayama, Junichi ^a   Yonemura, Akiko ^a   Kimura, Tomoatsu ^b   Matsuno, Hiroaki ^b  

^a DAIICHI SANKYO CO   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

^c IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; CD4 ANTIGEN; FAS ANTIBODY; MONOCLONAL ANTIBODY; R 125224; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE DESTRUCTION; CONTROLLED STUDY; DENTIN; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MALE; MONONUCLEAR CELL; MOUSE; MULTINUCLEAR CELL; NONHUMAN; OSTEOCLAST; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; STATISTICAL SIGNIFICANCE; SYNOVIUM; T LYMPHOCYTE ACTIVATION; TISSUE SLICE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD95; APOPTOSIS; ARTHRITIS, RHEUMATOID; CD4-POSITIVE T-LYMPHOCYTES; CELL DIVISION; CELLS, CULTURED; DENTIN; DISEASE MODELS, ANIMAL; HUMANS; MALE; MICE; MICE, INBRED ICR; MICE, SCID; OSTEOCLASTS; SYNOVIAL MEMBRANE;

EID: 0348111253     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.11322     Document Type: Article

References (39)

1. Harris ED Jr. Rheumatoid arthritis: pathophysiology and implications for therapy. N Engl J Med 1990;322:1277-89.
2. Goldring SR, Gravallese EM. Pathogenesis of bone lesions in rheumatoid arthritis. Curr Rheumatol Rep 2002;4:226-31.
3. Bromley M, Woolley DE. Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint. Arthritis Rheum 1984;27:968-75.
4. Fujikawa Y, Quinn JM, Sabokbar A, McGee JO, Athanasou NA. The human osteoclast precursor circulates in the monocyte fraction. Endocrinology 1996;137:4058-60.
5. Jimi E, Akiyama S, Tsurukai T, Okahashi N, Kobayashi K, Udagawa N, et al. Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function. J Immunol 1999;163:434-42.
6. Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Yano K, et al. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun 1998;253:395-400.
7. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A 1999;96:3540-5.
8. Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997;390:175-9.
9. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 1998;95: 3597-602.
10. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-76.
11. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999; 402:304-9.
12. Horwood NJ, Kartsogiannis V, Quinn JM, Romas E, Martin TJ, Gillespie MT. Activated T lymphocytes support osteoclast formation in vitro. Biochem Biophys Res Commun 1999;265:144-50.
13. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999;103:1345-52.
14. Roodman GD. Cell biology of the osteoclast. Exp Hematol 1999;27:1229-41.
15. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999;20:345-57.
16. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991;66:233-43.
17. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediate apoptosis. Nature 1992;356: 314-7.
18. Takahashi T, Tanaka M, Brannan CI, Jenkins NA, Copeland NG, Suda T, et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 1994;76:969-76.
19. Rieux Laucat F, Le Deist F, Hivroz C, Roberts IA, Debatin KM, Fischer A, et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 1995;268: 1347-9.
20. Nakajima T, Aono H, Hasunuma T, Yamamoto K, Shirai T, Hirohata K, et al. Apoptosis and functional Fas antigen in rheumatoid arthritis synoviocytes. Arthritis Rheum 1995;38: 485-91.
21. Hoa TT, Hasunuma T, Aono H, Masuko K, Kobata T, Yamamoto K, et al. Novel mechanisms of selective apoptosis in synovial T cells of patients with rheumatoid arthritis. J Rheumatol 1996;23: 1332-7.
22. Wooley PH, Luthra HS, Stuart JM, David CS. Type II collagen-induced arthritis in mice. I. Major histocompatibility complex (I region) linkage and antibody correlates. J Exp Med 1981;154: 688-700.
23. Yonehara S, Ishii A, Yonehara M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 1989;169: 1747-56.
24. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993;75:1169-78.
25. Trauth BC, Klas C, Peters AM, Matzku S, Moller P, Falk W, et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989;245:301-5.
26. Ogawa Y, Kuwahara H, Kimura T, Tani Y, Yonehara S, Shiraishi A, et al. Therapeutic effect of anti-Fas antibody on a collagen induced arthritis model. J Rheumatol 2001;28:950-5.
27. Sakai K, Matsuno H, Morita I, Nezuka T, Tsuji H, Shirai T, et al. Potential withdrawal of rheumatoid synovium by the induction of apoptosis using a novel in vivo model of rheumatoid arthritis. Arthritis Rheum 1998;41:1251-7.
28. Ichikawa K, Yoshida-Kato H, Ohtsuki M, Ohsumi J, Yamaguchi J, Takahashi S, et al. A novel murine anti-human Fas mAb which mitigates lymphadenopathy without hepatotoxicity. Int Immunol 2000;12:555-62.
29. Matsuno H, Yudoh K, Nakazawa F, Sawai T, Uzuki M, Nishioka K, et al. Antirheumatic effects of humanized anti-Fas monoclonal antibody in human rheumatoid arthritis/SCID mouse chimera. J Rheumatol 2002;29:1609-14.
30. Matsuno H, Sawai T, Nezuka T, Uzuki M, Tsuji H, Nishimoto N, et al. Treatment of rheumatoid synovitis with anti-reshaping human interleukin-6 receptor monoclonal antibody: use of rheumatoid arthritis tissue implants in the SCID mouse model. Arthritis Rheum 1998;41:2014-21.
31. Takayanagi H, Ogasawara K, Hida S, Chiba T, Murata S, Sato K, et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ. Nature 2000;408:600-5.
32. Firestein GS, Zvaifler NJ. How important are T cells in chronic rheumatoid synovitis? Arthritis Rheum 1990;33:768-73.
33. Kinne RW, Palombo-Kinne E, Emmrich F. T-cells in the pathogenesis of rheumatoid arthritis: villains or accomplices? Biochim Biophys Acta 1997;1360:109-41.
34. Takayanagi H, Iizuka H, Juji T, Nakagawa T, Yamamoto A, Miyazaki T, et al. Involvement of receptor activator of nuclear factor κB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 2000;43:259-69.
35. Gravallese EM, Manning C, Tsay A, Naito A, Pan C, Amento E, et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 2000;43:250-8.
36. Nakazawa F, Matsuno H, Yudoh K, Katayama R, Sawai T, Uzuki M, et al. Methotrexate inhibits rheumatoid synovitis by inducing apoptosis. J Rheumatol 2001;28:1800-8.
37. Fujikawa Y, Shingu M, Torisu T, Itonaga I, Masumi S. Bone resorption by tartrate-resistant acid phosphatase-positive multinuclear cells isolated from rheumatoid synovium. Br J Rheumatol 1996;35:213-7.
38. Chang JS, Quinn JM, Demaziere A, Bulstrode CJ, Francis MJ, Duthie RB, et al. Bone resorption by cells isolated from rheumatoid synovium. Ann Rheum Dis 1992;51:1223-9.
39. Suzuki Y, Tsutsumi Y, Nakagawa M, Suzuki H, Matsushita K, Beppu M, et al. Osteoclast-like cells in an in vitro model of bone destruction by rheumatoid synovium. Rheumatology (Oxford) 2001;40:673-82.